Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 37 Lung Neoplasms 12 Small Cell Lung Carcinoma 5 Nonsquamous Non-Small Cell Lung Cancer 2 Neoplasms 2 Carcinoma 2 Advanced Lung Cancer 2 Thoracic Neoplasms 1 Stomach Neoplasms 1 Squamous Non-Small Cell Lung Cancer SqNSCLC 1 Squamous NSCLC 1 Squamous Cell Non-small Cell Lung Cancer 1 Small Cell Lung Cancer Extensive Stage 1 SCLC 1 Respiratory Tract Diseases 1 Resectable Non-small Cell Lung Cancer 1 Resectable NSCLC 1 Radiation Pneumonitis 1 Osteosarcoma 1 Non-small Cell Lung Cancer Metastatic 1 Non-Squamous Non-Small Cell Lung Cancer 1 NSCLC 1 Multiple Primary Lung Cancer 1 Lung Diseases 1 Locally Advanced Non-Small Cell Lung Cancer 1 IIIA Stage Non-small Cell Lung Cancer 1 High-Risk Resectable NSCLC 1 Brain Neoplasms 1 Advanced Non-squamous Non-Small-Cell Lung Cancer 1 Advanced Non-Small Cell Lung Cancer 1

Interventions

Pemetrexed 14 Carboplatin 13 osimertinib 11 aflutinib 9 Drug Therapy 9 Gefitinib 8 Radiotherapy 6 Docetaxel 6 Cisplatin 6 pembrolizumab 5 anlotinib 5 Radiosurgery 5 Paclitaxel 5 icotinib 4 Vinorelbine 4 Gemcitabine 4 Erlotinib Hydrochloride 4 tislelizumab 3 camrelizumab 3 apatinib 3 HM781-36B 3 toripalimab 2 spartalizumab 2 rezivertinib 2 dacomitinib 2 Tyrosine Kinase Inhibitors 2 Thalidomide 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Platinum 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

NSCLC × sintilimab × Thoracic × Clear all

NCT06479759 2024-06-28

ACCLAIM

Shanghai Pulmonary Hospital, Shanghai, China

Phase 2 Recruiting

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡